VaxCorps

VaxCorpsVaxCorpsVaxCorps

VaxCorps

VaxCorpsVaxCorpsVaxCorps
  • Home
  • About Us
  • Alliance Partners
  • Blog & News
  • More
    • Home
    • About Us
    • Alliance Partners
    • Blog & News
  • Home
  • About Us
  • Alliance Partners
  • Blog & News

VaxCorps Overview

130+ investigative site locations across USA and Canada

130+ investigative site locations across USA and Canada

130+ investigative site locations across USA and Canada

Geographically diverse research centers with over 27,000 patients enrolled in over 25 vaccine trials, including COVID-19. Our sites have more depth and breadth of experience than any other vaccine network.

Access to more than 16M+ potential subjects nationwide

130+ investigative site locations across USA and Canada

130+ investigative site locations across USA and Canada

Established patient database with access to a wide range of healthy patients as well as patients with a variety of conditions.  

145 experience vaccine investigators

130+ investigative site locations across USA and Canada

145 experience vaccine investigators

APPI certified investigators (CPI) -

Pediatric, Adolescent, Adult, and Elderly average 11 years vaccine experience. 

850 support staff

IBC registration and PBMC capabilities at various sites

145 experience vaccine investigators

More than half ACRP certified CCRCs. 

Quality Assurance

IBC registration and PBMC capabilities at various sites

IBC registration and PBMC capabilities at various sites

Ex-FDA investigator on staff to oversee compliance and quality initiatives. 

IBC registration and PBMC capabilities at various sites

IBC registration and PBMC capabilities at various sites

IBC registration and PBMC capabilities at various sites

Who We Are

VaxCorps is a network of highly experienced, geographically diverse clinical research centers specializing in the conduct of vaccine trials in healthy adults, elderly, and pediatric populations

We have successfully conducted more than 500 Phase I - III vaccine clinical trials with the highest standards of research excellence

VaxCorps is committed to excellence - as industry leaders we effectively meet and exceed enrollment goals and adjust to tight timelines

Study Efficiencies

  • Regulatory Document Submission within 48 hours of receipt
  • Study start-up goal is enrollment ready within two weeks of receiving initial regulatory packets
  • Investigator and staff training 
  • Development of comprehensive recruitment plans for each site  
  • Network support staff allowing sites to focus on studies
  • VaxCorps sites employ in-house call center focusing on patient recruitment, engagement, and retention for all studies and sites 
  • Typical vaccine study has 175% of subjects pre-identified prior to First Patient First Visit (FPFV) 
  • Early patient education 
  • Investigator interaction with patients 
  • Flexible office hours 
  • Customer service oriented staff 
  • Internal goals and benchmarks to ensure our targets are met 
  • Patient stipend at each completed visit 





Studies Completed

Anthrax/Anthrax vaccine absorbed 

C.Difficile 

Chikakungaya 

Congenital Cytomegalovirus (CMV) 

COVID-19 

Ebola 

E. Coli 

Hepatitis B 

Herpes 

hMPV/PIV3 

Influenza 

Meningococcal (3) 

Norovirus 

Pertussis 

Pneumococcal

RSV 

Smallpox 

Staph Aureus 

Tdap 

Varicella 

Zika 

Zoster 

Our Alliance Partners

Copyright © 2022 VaxCorps - All Rights Reserved.

VaxCorps - The Clinical Research Experts

  • Privacy Policy
  • Terms and Conditions

Interested in learning more about VaxCorps?

CLICK HERE

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept